← Back to Search

Janus Kinase (JAK) Inhibitor

Ruxolitinib Cream for Prurigo (TRuE-PN1 Trial)

Phase 3
Recruiting
Research Sponsored by Incyte Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Baseline PN-related WI-NRS score ≥ 7
≥ 6 pruriginous lesions on ≥ 2 different body areas at screening and baseline having a treatment area <20% BSA
Must not have
Total estimated BSA treatment area (excluding the scalp) > 20%
Uncontrolled thyroid function
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 56 weeks
Awards & highlights
Pivotal Trial

Summary

This trial looks at how safe and well-tolerated a cream (Ruxolitinib) is in people with a skin condition (Prurigo Nodularis).

Who is the study for?
This trial is for individuals with Prurigo Nodularis (PN) who've had it for at least 3 months, have a moderate to severe itchiness score, and multiple itchy lesions in different body areas. Participants must not be pregnant or planning pregnancy and should avoid excessive UV exposure. Those with other skin conditions, uncontrolled thyroid issues, recent drug addiction history, or taking certain medications are excluded.
What is being tested?
The study is testing Ruxolitinib cream's safety and effectiveness against a placebo (Vehicle Cream) in treating PN. Participants will apply the creams to see if there's an improvement in their condition compared to those using the non-active cream.
What are the potential side effects?
Possible side effects of Ruxolitinib cream may include application site reactions like redness or irritation, headaches, dizziness, changes in blood counts leading to increased infection risk or bleeding problems. The exact side effects will be monitored throughout the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My nerve pain score is 7 or higher.
Select...
I have more than 6 itchy spots on at least 2 different parts of my body.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
Over 20% of my body, excluding my head, needs treatment.
Select...
My thyroid function is not under control.
Select...
I experience itching due to nerve issues or psychological reasons.
Select...
I have long-term itching not caused by nerve damage.
Select...
I am able to give my consent and am not under legal protection.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 56 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 56 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Worst-Itch Numeric Rating Scale (WI-NRS) ≥ 4-point improvement in WI-NRS score Response
Secondary study objectives
> 75% healed lesions from baseline in PAS at each postbaseline visit.
Change from baseline in Dermatology Life Quality Index (DLQI) score at each postbaseline visit.
Change from baseline in EQ-5D-5L score at each postbaseline visit.
+12 more

Side effects data

From 2020 Phase 3 trial • 631 Patients • NCT03745638
9%
Upper respiratory tract infection
6%
Nasopharyngitis
4%
Headache
1%
Pneumonia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Ruxolitinib 0.75% Cream BID
Vehicle Cream BID
Ruxolitinib 1.5% Cream BID

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Ruxolitinib 1.5% CreamExperimental Treatment1 Intervention
Participants apply ruxolitinib 1.5% cream topically to the affected areas as a thin film BID for 12 weeks during the DBVC period. Participants who have completed the treatment during DBVC period will apply ruxolitinib 1.5% cream the open label extension (OLE) period for up to 40 weeks.
Group II: Vehicle Cream BIDPlacebo Group1 Intervention
Participants apply ruxolitinib matching vehicle cream topically to the affected areas as a thin film twice daily (BID) for 12 weeks during the DBVC period. Participants who have completed the treatment during DBVC period will apply ruxolitinib 1.5% cream topically during the open label extension (OLE) period for up to 40 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ruxolitinib Cream
2018
Completed Phase 3
~740

Find a Location

Who is running the clinical trial?

Incyte CorporationLead Sponsor
391 Previous Clinical Trials
63,621 Total Patients Enrolled
5 Trials studying Prurigo
1,010 Patients Enrolled for Prurigo
Haq Nawaz, mdStudy DirectorIncyte Corporation

Media Library

Ruxolitinib Cream (Janus Kinase (JAK) Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05755438 — Phase 3
Prurigo Research Study Groups: Vehicle Cream BID, Ruxolitinib 1.5% Cream
Prurigo Clinical Trial 2023: Ruxolitinib Cream Highlights & Side Effects. Trial Name: NCT05755438 — Phase 3
Ruxolitinib Cream (Janus Kinase (JAK) Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05755438 — Phase 3
~67 spots leftby Nov 2025